Additive effect of non-alcoholic fatty liver disease on the development of diabetes in individuals with metabolic syndrome
Introduction
Metabolic syndrome (MetS) is a clustering of several atherogenic metabolic abnormalities that include central obesity, impaired glucose metabolism, dyslipidemia, and hypertension [1]. Insulin resistance is considered to play a fundamental role in MetS and leads to the most of the abnormalities observed in MetS [2], [3]. Non-alcoholic fatty liver disease (NAFLD) is characterized by lipid deposition in hepatocytes and includes wide spectrum of liver damage from simple steatosis to steatohepatitis and advanced fibrosis [4]. Currently, NAFLD is considered as the hepatic manifestation of MetS, with insulin resistance as the main pathogenic mechanism [5], [6]. Insulin resistance is a major factor in the pathogenesis of type 2 diabetes and is closely linked to cardiovascular disease [3], [7]. Diagnosing and treating MetS is important since individuals with MetS are at increased risk of developing type 2 diabetes and cardiovascular disease [1], [8]. Several studies have reported that NAFLD contribute to the development of type 2 diabetes and is associated with increased cardiovascular risk [9], [10], [11], [12].
MetS and NAFLD share a common pathophysiologic mechanism [2], [5]. Many individuals with MetS also have NAFLD [13]. Thus, the coexistence of NAFLD may have effect on the contribution of MetS to the development of diabetes. However, the additive role of NAFLD on the incident diabetes risk in individuals with MetS is uncertain. Also, accumulating evidence suggests that the association of NAFLD with insulin resistance is independent of obesity and other metabolic components [6]. However, the magnitude of diabetes risk in NAFLD patients without MetS or in MetS patients without NAFLD is unclear, given the paucity of data on the separate effects of MetS and NAFLD on the development of diabetes [14].
It is important to understand the role of metabolic syndrome and NAFLD on the development of diabetes. The current longitudinal cohort study evaluated the separate and combined effects of metabolic syndrome and NAFLD on incident diabetes risk.
Section snippets
Patients and methods
We used the same data sources and methods as our previous study [9]. These are described below, along with additional methodological details.
Results
Overall, the participants were relatively young and not obese, with a mean BMI of 23.6 ± 2.8 kg/m2. Mean age of participants was 44.6 years and 68.9% of the participants were men. MetS and NAFLD was present at baseline in 16.7% and 29.2% of the participants, respectively. There was a gender difference in the prevalence of metabolic syndrome and NAFLD with more men (21.3% and 38.9%, respectively) affected by those disorders than women (6.5% and 9.7%, respectively). While 64.6% of individuals with
Discussion
In this study, the presence of NAFLD further increased the risk of incident diabetes in individuals with MetS. The presence of MetS increases the risk for type 2 diabetes.[8] NAFLD is considered as the hepatic manifestation of MetS, with insulin resistance as the common pathophysiologic mechanism, which is why many individuals with MetS have NAFLD [5], [6], [13]. Presently, 64.6% of individuals with MetS had concurrent NAFLD and the risk of diabetes among subjects with MetS was exaggerated by
Conflict of interest
The authors declared that they do not have anything to disclose regarding conflict of interest with respect to this manuscript.
Acknowledgements
This work was supported by a grant (SMX1161861) from the Samsung Biomedical Research Institute, Republic of Korea. This funding source played no role in the study design, collection, analysis, and interpretation of data, the writing of the manuscript, and the decision to submit the manuscript for publication. E.J.R is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
References (34)
- et al.
Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome
Dig Liver Dis
(2015) - et al.
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease
J Biol Chem
(2004) - et al.
Investigation of hepatic gluconeogenesis pathway in non-diabetic Asian Indians with non-alcoholic fatty liver disease using in vivo ((31)P) phosphorus magnetic resonance spectroscopy
Atherosclerosis
(2009) - et al.
European Association for the Study of D. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes
Diabetes Care
(2005) - et al.
Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome
Diabetologia
(1991) Insulin resistance and cardiovascular disease
J Clin Invest
(2000)- et al.
Characteristics and diagnosis of NAFLD/NASH
J Gastroenterol Hepatol
(2013) - et al.
Review: the role of insulin resistance in nonalcoholic fatty liver disease
J Clin Endocrinol Metab
(2006) - et al.
Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels in nondiabetic subjects
Am J Gastroenterol
(2010) The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes
Diabetologia
(2003)
Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study
Am J Epidemiol
Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study
Diabetes Care
Metab: Clin Exp
Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease
N Engl J Med
Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?
Eur Heart J
Diagnosis of non-alcoholic fatty liver disease (NAFLD)
Diabetologia
Fatty liver increases the association of metabolic syndrome with diabetes and atherosclerosis
Diabetes Care
Cited by (12)
Metabolic syndrome and transaminases: systematic review and meta-analysis
2023, Diabetology and Metabolic SyndromeAge-and Sex-Specific Differences in Distribution of Cardiometabolic Diseases and Associations of Hand-Grip Strength Indices with Type 2 Diabetes in Korean Adults
2022, Metabolic Syndrome and Related DisordersThe effect of liraglutide on nonalcoholic fatty liver disease in type 2 diabetes mellitus
2020, International Journal of Diabetes in Developing CountriesA round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?
2019, Acta Diabetologica
- 1
Ji Cheol Bae and Soo Kyoung Kim contributed equally to this work as first authors.